Personalized peptide vaccines: a new therapeutic modality for cancer

Area of Science:

• Oncology
• Immunology
• Vaccinology

Background:

• Therapeutic cancer vaccines have historically shown limited success despite numerous clinical trials.
• There is a critical need for novel treatment protocols that can elicit objective responses in cancer patients.

Purpose of the Study:

• To review and evaluate two novel therapeutic cancer vaccine protocols.
• To assess the efficacy of a personalized vaccine approach considering individual immune responses.
• To examine a combination therapy strategy designed to overcome major histocompatibility complex (MHC)-loss variants in cancer cells.

Main Methods:

• Review of clinical trial data for classical (non-personalized) peptide vaccines.
• Analysis of outcomes from personalized peptide vaccines tailored to patient-specific cytotoxic T lymphocyte (CTL) responses.
• Evaluation of a combination therapy involving personalized vaccination and low-dose estramustine in hormone-refractory prostate cancer.

Main Results:

• Classical peptide vaccines demonstrated 0% objective response rates.
• Personalized vaccines achieved an 11.1% objective response rate in advanced cancers, with over 20% in malignant glioma and cervical cancers.
• Personalized vaccination alone resulted in a >= 50% prostate-specific antigen (PSA) decrease in 8.7% of prostate cancer patients; this increased to 54% when combined with low-dose estramustine.

Conclusions:

• Personalized peptide vaccines offer improved objective response rates compared to non-personalized approaches.
• Combination therapy, specifically personalized vaccination with chemotherapy (e.g., estramustine), represents a promising new treatment modality for various cancers.
• Further investigation into personalized vaccines combined with chemotherapy is warranted to optimize cancer treatment strategies.